Page last updated: 2024-10-26

etidronate and Idiopathic Parkinson Disease

etidronate has been researched along with Idiopathic Parkinson Disease in 5 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

ExcerptRelevanceReference
"Urinary deoxypyridinoline, a bone resorption marker, decreased by 46."2.73Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007)
"After patients with osteoporosis are identified, the challenge is to treat them appropriately."2.47Treatments for osteoporosis in people with a disability. ( Smith, EM, 2011)
"Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures."2.44Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smith, EM1
Sato, Y2
Iwamoto, J3
Honda, Y2
Matsumoto, H1
Takeda, T1
Paterson, CR1
Feely, J1

Reviews

2 reviews available for etidronate and Idiopathic Parkinson Disease

ArticleYear
Treatments for osteoporosis in people with a disability.
    PM & R : the journal of injury, function, and rehabilitation, 2011, Volume: 3, Issue:2

    Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Etidronic Acid; Hu

2011
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
    Current medical research and opinion, 2008, Volume: 24, Issue:5

    Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf

2008

Trials

2 trials available for etidronate and Idiopathic Parkinson Disease

ArticleYear
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
    Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:12

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administratio

2011
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Neurology, 2007, Mar-20, Volume: 68, Issue:12

    Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo

2007

Other Studies

1 other study available for etidronate and Idiopathic Parkinson Disease

ArticleYear
Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine.
    British medical journal (Clinical research ed.), 1983, May-21, Volume: 286, Issue:6378

    Topics: Acromegaly; Bromocriptine; Calcitriol; Danazol; Endometriosis; Etidronic Acid; Female; Fibrocystic B

1983